Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Fig. 1

SF3B1 expression in PDAC. A mRNA levels of SF3B1 adjusted for ACTB gene expression in PDAC FFPE samples compared with non-tumoral adjacent tissue (NTAT). B SF3B1 IHC analysis in PDAC FFPE samples vs. NTAT. C Representative IHC 20X-image; SF3B1 nuclear immunostaining in non-tumoral adjacent tissue is evident in acinar and ductal cells (left panel) and in cancer cells (right panel). D SF3B1 mRNA levels in E-MTAB-1791 [22] comparing PDAC and healthy controls. E SF3B1 mRNA levels in GSE15471 [19] comparing PDAC and NTAT used as a control. F Correlation of SF3B1 mRNA levels with clinical stage, lymph node involvement and distant metastasis (according to WHO) in PanCancer cohort [5]. Data represents mean ± SEM. Asterisks indicate significant differences (*p < 0.05; **p < 0.01; ***p < 0.001)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us